BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20451957)

  • 1. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus.
    Mortensen SB; Larsen SB; Grove EL; Kristensen SD; Hvas AM
    Thromb Res; 2010 Oct; 126(4):e318-22. PubMed ID: 20451957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
    van Werkum JW; Topcu Y; Postma S; Kelder JC; Hackeng CM; ten Berg JM; Verheugt FW
    Thromb Haemost; 2008 Mar; 99(3):637-9. PubMed ID: 18327417
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus.
    Ariturk Z; Islamoglu Y; Gündüz E; Yavuz C; Cil H; Tekbas E; Soydinc S; Kaya H; Elbey MA
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):617-21. PubMed ID: 22774402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
    Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
    Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
    Serebruany V; Pokov I; Kuliczkowski W; Chesebro J; Badimon J
    Thromb Haemost; 2008 Jul; 100(1):76-82. PubMed ID: 18612541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor aspirin response in diabetic patients presenting with acute coronary syndromes: results using a near patient test.
    Amoah V; Smallwood A; Worrall AP; Lovatt T; Armesilla AL; Nevill AM; Cotton JM
    Thromb Res; 2011 Aug; 128(2):196-9. PubMed ID: 21543109
    [No Abstract]   [Full Text] [Related]  

  • 9. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
    Würtz M; Grove EL; Kristensen SD; Hvas AM
    Heart; 2010 Mar; 96(5):368-71. PubMed ID: 19910291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease.
    Addad F; Chakroune T; Asma A; Abderazek F; Zohra D; Ghrissi I; Hassine M; Gamra H; Elalamy I
    Thromb Res; 2009 Feb; 123(4):640-3. PubMed ID: 18602138
    [No Abstract]   [Full Text] [Related]  

  • 11. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
    Dillinger JG; Drissa A; Sideris G; Bal dit Sollier C; Voicu S; Manzo Silberman S; Logeart D; Drouet L; Henry P
    Am Heart J; 2012 Oct; 164(4):600-606.e1. PubMed ID: 23067920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
    Larsen SB; Grove EL; Kristensen SD; Hvas AM
    Thromb Haemost; 2013 May; 109(5):920-9. PubMed ID: 23407706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
    Angiolillo DJ; Bernardo E; Sabaté M; Jimenez-Quevedo P; Costa MA; Palazuelos J; Hernández-Antolin R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Guzman LA; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2007 Oct; 50(16):1541-7. PubMed ID: 17936152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes.
    Bliden KP; Tantry US; DiChiara J; Gurbel PA
    Circ Cardiovasc Interv; 2011 Apr; 4(2):118-20. PubMed ID: 21505165
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
    Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease.
    Gao F; Wang ZX; Men JL; Ren J; Wei MX
    Chin Med J (Engl); 2011 Jun; 124(11):1731-4. PubMed ID: 21740787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond glucose levels in diabetic patients with coronary artery disease: platelet activity and non-responsiveness to antiplatelet therapy.
    Shantsila E; Lip GY
    Thromb Haemost; 2008 Jul; 100(1):7-8. PubMed ID: 18612528
    [No Abstract]   [Full Text] [Related]  

  • 19. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
    Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
    Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.